Search

Search Constraints

You searched for: Author/Creator Raetz, Elizabeth A.

Search Results

12. Ikaros deletions in BCR–ABL‐negative childhood acute lymphoblastic leukemia are associated with a distinct gene expression signature but do not result in intrinsic chemoresistance. Issue 10 (29th June 2014)

13. Improving infectious adverse event reporting for children and adolescents enrolled in clinical trials for acute lymphoblastic leukemia: A report from the Children's Oncology Group. Issue 11 (9th September 2022)

14. Klinefelter syndrome and 47, XYY syndrome in children with B cell acute lymphoblastic leukaemia. (19th July 2016)

15. Longitudinal analysis of quality‐of‐life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children's Oncology Group AALL0932 trial. Issue 3 (7th November 2017)

16. Mixed‐phenotype acute leukemia: A cohort and consensus research strategy from the Children's Oncology Group Acute Leukemia of Ambiguous Lineage Task Force. Issue 3 (29th October 2019)

17. No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy. Issue 6 (7th March 2019)

18. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group. Issue 3 (1st November 2017)

19. Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621. Issue 9 (20th March 2022)

20. Prognostic impact of minimal residual disease at the end of consolidation in NCI standard‐risk B‐lymphoblastic leukemia: A report from the Children's Oncology Group. Issue 4 (9th February 2021)